These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 15563636

  • 1. Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor.
    Bonniaud P, Margetts PJ, Kolb M, Schroeder JA, Kapoun AM, Damm D, Murphy A, Chakravarty S, Dugar S, Higgins L, Protter AA, Gauldie J.
    Am J Respir Crit Care Med; 2005 Apr 15; 171(8):889-98. PubMed ID: 15563636
    [Abstract] [Full Text] [Related]

  • 2. SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model.
    Fu K, Corbley MJ, Sun L, Friedman JE, Shan F, Papadatos JL, Costa D, Lutterodt F, Sweigard H, Bowes S, Choi M, Boriack-Sjodin PA, Arduini RM, Sun D, Newman MN, Zhang X, Mead JN, Chuaqui CE, Cheung HK, Zhang X, Cornebise M, Carter MB, Josiah S, Singh J, Lee WC, Gill A, Ling LE.
    Arterioscler Thromb Vasc Biol; 2008 Apr 15; 28(4):665-71. PubMed ID: 18202322
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis.
    Higashiyama H, Yoshimoto D, Kaise T, Matsubara S, Fujiwara M, Kikkawa H, Asano S, Kinoshita M.
    Exp Mol Pathol; 2007 Aug 15; 83(1):39-46. PubMed ID: 17274978
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis.
    Grygielko ET, Martin WM, Tweed C, Thornton P, Harling J, Brooks DP, Laping NJ.
    J Pharmacol Exp Ther; 2005 Jun 15; 313(3):943-51. PubMed ID: 15769863
    [Abstract] [Full Text] [Related]

  • 5. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.
    DaCosta Byfield S, Major C, Laping NJ, Roberts AB.
    Mol Pharmacol; 2004 Mar 15; 65(3):744-52. PubMed ID: 14978253
    [Abstract] [Full Text] [Related]

  • 6. Transforming growth factor-beta type 1 receptor (ALK5) and Smad proteins mediate TIMP-1 and collagen synthesis in experimental intestinal fibrosis.
    Medina C, Santos-Martinez MJ, Santana A, Paz-Cabrera MC, Johnston MJ, Mourelle M, Salas A, Guarner F.
    J Pathol; 2011 Aug 15; 224(4):461-72. PubMed ID: 21465486
    [Abstract] [Full Text] [Related]

  • 7. Gene expression profiling demonstrates that TGF-beta1 signals exclusively through receptor complexes involving Alk5 and identifies targets of TGF-beta signaling.
    Karlsson G, Liu Y, Larsson J, Goumans MJ, Lee JS, Thorgeirsson SS, Ringnér M, Karlsson S.
    Physiol Genomics; 2005 May 11; 21(3):396-403. PubMed ID: 15769904
    [Abstract] [Full Text] [Related]

  • 8. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts.
    Mori Y, Ishida W, Bhattacharyya S, Li Y, Platanias LC, Varga J.
    Arthritis Rheum; 2004 Dec 11; 50(12):4008-21. PubMed ID: 15593186
    [Abstract] [Full Text] [Related]

  • 9. Glycosyltransferases and glycosaminoglycans in bleomycin and transforming growth factor-β1-induced pulmonary fibrosis.
    Venkatesan N, Tsuchiya K, Kolb M, Farkas L, Bourhim M, Ouzzine M, Ludwig MS.
    Am J Respir Cell Mol Biol; 2014 Mar 11; 50(3):583-94. PubMed ID: 24127863
    [Abstract] [Full Text] [Related]

  • 10. The expression of CSRP2 encoding the LIM domain protein CRP2 is mediated by TGF-beta in smooth muscle and hepatic stellate cells.
    Herrmann J, Borkham-Kamphorst E, Haas U, Van de Leur E, Fraga MF, Esteller M, Gressner AM, Weiskirchen R.
    Biochem Biophys Res Commun; 2006 Jul 14; 345(4):1526-35. PubMed ID: 16735029
    [Abstract] [Full Text] [Related]

  • 11. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.
    Gellibert F, de Gouville AC, Woolven J, Mathews N, Nguyen VL, Bertho-Ruault C, Patikis A, Grygielko ET, Laping NJ, Huet S.
    J Med Chem; 2006 Apr 06; 49(7):2210-21. PubMed ID: 16570917
    [Abstract] [Full Text] [Related]

  • 12. Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-beta in human umbilical vein endothelial cells.
    Ota T, Fujii M, Sugizaki T, Ishii M, Miyazawa K, Aburatani H, Miyazono K.
    J Cell Physiol; 2002 Dec 06; 193(3):299-318. PubMed ID: 12384983
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis.
    de Gouville AC, Boullay V, Krysa G, Pilot J, Brusq JM, Loriolle F, Gauthier JM, Papworth SA, Laroze A, Gellibert F, Huet S.
    Br J Pharmacol; 2005 May 06; 145(2):166-77. PubMed ID: 15723089
    [Abstract] [Full Text] [Related]

  • 14. Differences in the fibrogenic response after transfer of active transforming growth factor-beta1 gene to lungs of "fibrosis-prone" and "fibrosis-resistant" mouse strains.
    Kolb M, Bonniaud P, Galt T, Sime PJ, Kelly MM, Margetts PJ, Gauldie J.
    Am J Respir Cell Mol Biol; 2002 Aug 06; 27(2):141-50. PubMed ID: 12151305
    [Abstract] [Full Text] [Related]

  • 15. Transforming growth factor-beta receptor type 1 (TGFbetaRI) kinase activity but not p38 activation is required for TGFbetaRI-induced myofibroblast differentiation and profibrotic gene expression.
    Kapoun AM, Gaspar NJ, Wang Y, Damm D, Liu YW, O'young G, Quon D, Lam A, Munson K, Tran TT, Ma JY, Murphy A, Dugar S, Chakravarty S, Protter AA, Wen FQ, Liu X, Rennard SI, Higgins LS.
    Mol Pharmacol; 2006 Aug 06; 70(2):518-31. PubMed ID: 16707625
    [Abstract] [Full Text] [Related]

  • 16. SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells.
    Matsuyama S, Iwadate M, Kondo M, Saitoh M, Hanyu A, Shimizu K, Aburatani H, Mishima HK, Imamura T, Miyazono K, Miyazawa K.
    Cancer Res; 2003 Nov 15; 63(22):7791-8. PubMed ID: 14633705
    [Abstract] [Full Text] [Related]

  • 17. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
    Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A, Wong DH, Wick W, Higgins LS, Weller M.
    Cancer Res; 2004 Nov 01; 64(21):7954-61. PubMed ID: 15520202
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of ALK5 as a new approach to treat liver fibrotic diseases.
    de Gouville AC, Huet S.
    Drug News Perspect; 2006 Mar 01; 19(2):85-90. PubMed ID: 16628263
    [Abstract] [Full Text] [Related]

  • 19. Expression of transforming growth factor-beta type I and type II receptors is altered in rat lungs undergoing bleomycin-induced pulmonary fibrosis.
    Zhao Y, Shah DU.
    Exp Mol Pathol; 2000 Oct 01; 69(2):67-78. PubMed ID: 11001857
    [Abstract] [Full Text] [Related]

  • 20. Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptors.
    Shi-Wen X, Rodríguez-Pascual F, Lamas S, Holmes A, Howat S, Pearson JD, Dashwood MR, du Bois RM, Denton CP, Black CM, Abraham DJ, Leask A.
    Mol Cell Biol; 2006 Jul 01; 26(14):5518-27. PubMed ID: 16809784
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.